Navigation Links
Study Challenges Potassium Guidelines for Heart Attack Patients
Date:1/10/2012

TUESDAY, Jan. 10 (HealthDay News) -- Heart attack patients whose blood potassium levels are within a certain range are less likely to die than those with levels of the mineral below or above that range, says a new study that challenges current recommendations for potassium levels in heart attack patients.

Researchers looked at data from nearly 39,000 heart attack patients admitted to 67 U.S. hospitals between 2000 and 2008. Of those patients, nearly 7 percent died while they were hospitalized.

The death rate for patients with blood potassium levels of between 3.5 and less than 4 mEq/L (milliEquivalents per liter) was 4.8 percent, about the same as the 5 percent death rate among those with levels of 4 mEq/L to less than 4.5 mEq/L.

But mortality rose to 10 percent for those with levels of 4.5 to less than 5 mEq/L, and was even higher for those with levels greater than 5 mEq/L, the investigators found.

Patients with potassium levels of less than 3.5 mEq/L also had a higher death rate than those with levels of between 3.5 and less than 4.5 mEq/L, Dr. Abhinav Goyal, of the Emory Rollins School of Public Health in Atlanta, and colleagues, reported in the study published in the Jan. 11 issue of the Journal of the American Medical Association.

Currently, professional societies and experts recommend that potassium levels in heart attack patients should be maintained between 4.0 and 5.0 mEq/L or even 4.5 to 5.5 mEq/L, the researchers noted.

"In conclusion, our large study of patients with AMI [acute myocardial infarction, or heart attack] challenges current clinical practice guidelines that endorse maintaining serum potassium levels between 4.0 and 5.0 mEq/L," the study authors wrote.

The guidelines are based on small, older studies that focused only on ventricular arrhythmias and not mortality, and were conducted before the routine use of beta-blockers, treatments to quickly clear blockages and restore blood flow, and other treatment advances, the researchers said.

"Our data suggest that the optimal range of serum potassium levels in AMI patients may be between 3.5 and 4.5 mEq/L and that potassium levels of greater than 4.5 mEq/L are associated with increased mortality and should probably be avoided," the study authors noted.

In an accompanying editorial, Dr. Benjamin Scirica and Dr. David Morrow of Brigham and Women's Hospital and Harvard Medical School wrote that proving maintaining certain potassium levels prevents deaths would require a clinical trial that randomly assigns patients to different treatments, which is unlikely to ever be done.

"Thus, decisions about care must be formulated on the basis of best available information," the editorialists wrote.

Given that it is inexpensive and relatively low-risk, it's "reasonable" to avoid abnormally low potassium levels of less than 3.5 mEq/L in heart attack patients.

"However, based on the report by Goyal [and colleagues], viewed together with previous smaller studies . . . routinely targeting levels greater than 4.5 mEq/L, do not appear justified."

More information

The U.S. National Heart, Lung, and Blood Institute has more about heart attack.

-- Robert Preidt

SOURCE: Journal of the American Medical Association, news release, Jan. 10, 2012


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Lower risk of death linked with access to key attributes of primary care, UC Davis study shows
2. Diabetes study shines spotlight on lifestyle interventions
3. Grief Is a Real Heartbreaker, Study Finds
4. Study finds federal amendments increased gun sales diverted to criminals
5. Nicotine Patches, Gums Wont Help Smokers Quit Long-Term: Study
6. Power of Acupuncture to Ease Migraines Questioned in Study
7. Exercise May Help Those at Higher Risk for Alzheimers: Study
8. Short Delay in Treating Blood Pressure Safe for Diabetics: Study
9. New study supports view that Lewy bodies are not the primary cause of cell death in PD
10. PSA Test for Prostate Cancer Doesnt Save Lives: Study
11. Study shows no evidence of a mortality benefit to PSA screening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... December 09, 2016 , ... Flottman ... and outserts. As a means of expanding capabilities Flottman has added a ... to individually code professional inserts (PIs) and patient package inserts (PPIs) that will ...
(Date:12/9/2016)... , ... December 09, 2016 , ... An inventor from ... to safely ride all types of amusement park rides. , The patent-pending SAFETY STRAP ... is easy to use and could be set up in a matter of minutes, ...
(Date:12/9/2016)... ... December 09, 2016 , ... "I had a terrible time trying ... Va. "I thought that if the nebulizer had a more child-friendly design, then children ... , He developed the patent-pending NEBY to avoid the need to deliver medication via ...
(Date:12/8/2016)... MA (PRWEB) , ... December 08, 2016 , ... ... Workers Compensation Research Institute (WCRI) officially opened registration today for its 33rd ... Hotel in Boston, MA . , The theme of the conference is “Persistent ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... offering Medication Therapy Management (MTM), adherence, and other pharmacist-delivered patient care services, has ... general counsel and Eric Hoessel to vice president of sales. , Litsinger ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... , Dec 9, 2016 Research ... Screening Market - Forecast to 2021" report to their ... ... of open innovative models in the pharmaceutical and biotechnology industry ... and rising government funding. Emerging markets and growing research activities ...
(Date:12/9/2016)...  RxWiki Inc., a digital health company that powers ... thousands of pharmacies through its Digital Pharmacist SaaS platform, ... "50 on Fire" Award in the Health and Life ... the award as one of Austin,s fastest growing companies," ... RxWiki. "Our platform gives independent retail pharmacies the digital ...
(Date:12/9/2016)... , Dec. 9, 2016  Forge Therapeutics, ... AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) ... ,LpxC, for the treatment of bacterial infections including ... been recognized as an attractive antibacterial target for ... lack of suitable chemical starting points has hampered ...
Breaking Medicine Technology: